Glioblastoma (GBM) is one of the most aggressive cancers of the brain. Despite extensive
research over the last several decades, the survival rates for GBM have not improved and …

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Surgery
followed by chemotherapy and radiotherapy remains the standard treatment strategy for …

Glioblastoma multiforme is one of the most prevalent and malignant forms of central nervous
system tumors. The treatment of glioblastoma remains a great challenge due to its location …

Biodegradable polymeric nanoparticles have the potential to be safer alternatives to viruses
for gene delivery; however, their use has been limited by poor efficacy in vivo. In this work …

Localized and controlled delivery of chemotherapeutics directly in brain-tumor for prolonged
periods may radically improve the prognosis of recurrent glioblastoma. Here, we report a …

Glioma stem cells (GSC) possess tumor-initiating potential and are relatively resistant to
conventional chemotherapy and irradiation. Thus, they are considered to be major drivers …

Glioblastoma multiforme (GBM) is highly invasive and uniformly fatal, with median survival<
20 months after diagnosis even with the most aggressive treatment that includes surgery …

Glioblastoma multiforme (GBM) has few clinically approved therapeutic regimens. One of
these therapeutic options includes placing biodegradable wafers releasing BCNU …

Background Glioblastoma (GBM) is the most common and aggressive primary brain tumor in
adults. Despite the gold standard treatment combining surgical resection, radiation and …

Despite the emergence of cutting-edge therapeutic strategies and tremendous progress in
research, a complete cure of glioma remains elusive. The heterogenous nature of tumor …